The U.S. Preventive Services Task Force released a recommendation this week calling on health care providers to prescribe all approved PrEP options for people at ...
The federal Food and Drug Administration has approved Apretude (extended-release cabotegravir), the first long-acting injectable option for HIV prevention. The shots, which are administered by a ...
See more of our trusted coverage when you search. Prefer Newsweek on Google to see more of our trusted coverage when you search. A new pre-exposure prophylaxis (PrEP) drug has shown promise as a ...
The first ever injectable drug that can prevent HIV has been approved for use in England and Wales. The drug, cabotegravir, would benefit an estimated 1,000 people at risk of HIV in England and Wales.
Offering diverse PrEP options enhances adherence and reduces HIV cases, with injectable forms showing promise due to less frequent dosing. The study found that MSM in Australia prefer various PrEP ...
Hosted on MSN
HIV: Monthly PrEP drug candidate shows promise
A new pre-exposure prophylaxis (PrEP) drug has shown promise as a once-monthly oral pill to help prevent HIV. PrEP plays a key part in reducing the number of new HIV infections by stopping the virus ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results